BioTime Could Be The Next Acquisition Target In The Stem Cell Sector – Seeking Alpha
|
BioTime Could Be The Next Acquisition Target In The Stem Cell Sector
Seeking Alpha With Ocata Therapeutics being acquired by Astellas Pharma, a very similar company based on its therapeutic stem cell platform and IP, BioTime, Inc., could be next. Japan's recent legislation has created an opportunity for regenerative medicine … |
